SPONSORED BY SICA MEDIA AND DISSEMINATED ON BEHALF OF CITIUS PHARMACEUTICALS, INC.*

Good Morning Market Enthusiast,

If you’re still waiting for a signal, the opening bell is your final warning. It is already up 8% in premarket, and the volume is surging. The fuse has officially been lit for Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) as it begins its sprint toward that $6.00 analyst target. Retail is flooding in after yesterday’s massive oncology news, and the market is finally realizing the math doesn't add up at these levels. The chance to get ahead of the stampede is disappearing in real-time—stop watching from the sidelines and check out CTXR right now.. (2)(4)(5)

(4)

The momentum is shifting, the charts are screaming, and if you aren’t looking at the math right now, you’re missing the biggest "glitch" in the biopharmaceutical space. While the rest of the crowd is distracted by whatever macro noise is hitting the wires, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is quietly sitting on a mountain of value that is beginning to erupt. 

The Valuation "Glitch": A $70 Million Wallet for $18 Million (1)(2)(4)(5)(6)(11)

Let’s start with the math that makes most spreadsheet enthusiasts short-circuit. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is currently the majority owner (holding approximately 78%) of a subsidiary called Citius Oncology (Nasdaq: CTOR).

As of this morning, CTOR has a market cap of roughly $89 million. If you do the math, the 78% stake held by Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is worth about $69 million. Now, look at the current market cap of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) itself: it’s hovering around just $18 million.

Think about that. You are looking at a parent company being valued at less than a third of the value of its stake in a single subsidiary. And that’s before you even count their multi-Billion dollar pipeline, their cash on hand, or their proprietary tech. It’s a valuation disconnect so wide you could drive a fleet of Lambos through it. When the retail crew finally realizes the decimal point is in the wrong place, the FOMO is going to be legendary.

Fresh Off the Wires: The LYMPHIR™ Expansion (March 10, 2026) (2)(4)(5)(6)(11)

If you wanted a reason for those "stellar days" to return, you just got it. Literally yesterday, March 10, 2026, the company dropped massive news. Their subsidiary, Citius Oncology, reported positive topline results from a Phase 1 study evaluating their lead therapy, LYMPHIR™, in combination with Keytruda (pembrolizumab).

This isn’t just a small update; it’s a game-changer. The study focused on patients with recurrent or refractory gynecologic cancers—ovarian and endometrial—who have very few options left. The results? A 24% objective response rate and a 48% clinical benefit rate. In a patient population that is notoriously difficult to treat, these numbers are lighting up the screens of oncology specialists everywhere.

This proves that LYMPHIR™ isn't just a "one-trick pony" for lymphoma; it has the potential to become a backbone therapy that enhances other blockbuster treatments. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is no longer just a "development" story; they are an "expansion" story.

(5)

Shot on Goal #1: LYMPHIR™ – The Revenue Engine is Purring (1)(2)(4)(5)(7)

For those who are tired of waiting for "Phase 2 results" from every other micro-cap, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has already crossed the finish line. They have an FDA-cleared therapy that is officially on the market.

Launched in December 2025, LYMPHIR™ is a targeted immunotherapy for a rare form of non-Hodgkin lymphoma (CTCL). In its very first quarter of commercialization, it generated $3.9 million in revenue. That is real cash, from real patients, in the real world.

The company has deployed an AI-enabled commercial platform to target prescribers with laser precision, and specialty distributors have already moved the product nationwide. With a U.S. market potential of $400+ million and expansion deals already inked for Europe and the Middle East, this revenue stream is just the base camp. The peak is a lot higher.

Shot on Goal #2: Mino-Lok® – The $1.8 Billion Category Killer (1)(2)(4)(5)(6)(11)

While the oncology side of the business is making headlines, the "sleeping giant" in the Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) portfolio is Mino-Lok®.

If you’ve ever seen a patient with a Central Venous Catheter (CVC), you know how vital they are. But you also know the nightmare of infections. Every year, 500,000 of these catheters get infected, and the current "cure" is to rip the old one out and shove a new one in. It’s painful, it’s traumatizing, and it costs hospitals $10,000 per pop.

Mino-Lok® is the first and only solution designed to salvage those catheters. Instead of "rip and replace," you use Mino-Lok® to clear the infection while the catheter stays in place.
 

• The Status: Phase 3 is complete.
• The Results: They hit the primary and secondary endpoints with "very high statistical significance."
• The Potential: A $1 Billion U.S. market and $1.8 Billion globally.
   

The company is currently in active discussions with the FDA to finalize the path to approval. When this clears the final hurdle, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) isn't just a player in the market—they are the market.

Shot on Goal #3: Halo-Lido – Disrupting the Undisrupted (1)(2)(4)(5)(6)(10)(11)

Finally, we have Halo-Lido. Half of all adults over 50 suffer from hemorrhoids. It’s a massive market currently dominated by "meh" over-the-counter creams. There is currently zero FDA-cleared prescription competition.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is changing that. They’ve completed a successful Phase 2b trial for a proprietary formulation that provides both anti-inflammatory and anesthetic relief. They are moving toward a Phase 3 trial that could turn a sleepy corner of the pharmacy into a high-margin prescription powerhouse.

The Technical Setup: A Coiled Spring (1)(2)(4)(5)(6)(10)(11)

If you look at the chart for Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), you see a chart that is itching for a breakout. After finding a hard floor at $0.67 on March 3rd, the volume started to pour in. We saw a massive surge to $1.00, and now we are seeing healthy consolidation.

The market is pricing in the company’s push for Nasdaq compliance. A sustained move back above that $1.00 mark would be a massive psychological trigger, likely pulling in a whole new wave of momentum players who have been waiting on the sidelines.

And don't forget the analyst targets. The average price target is sitting at $6.00. From where we are today, that is a potential move of over 500%. When you combine that kind of upside with the fact that the founders have $26.5 million of their own cash on the line (with CEO Leonard Mazur personally putting in $22.5 million), you realize this isn't just another ticker. This is a mission.

But the commitment doesn’t stop with the founders' bank accounts. In a move that shows exactly how savvy this management team is, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) recently secured a $3.8 million non-dilutive capital injection from the New Jersey Economic Development Authority (NJEDA).

For those who aren’t familiar with the NJEDA’s Net Operating Loss (NOL) program, here’s why this is a massive win for the retail crowd: this is essentially "found money." It’s a cash infusion that doesn’t require the company to sell a single new share or dilute your position. While other companies in this space are often forced to go to the market with cap in hand just to keep the lights on, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is turning its tax assets into a multi-million dollar war chest. This is professional-grade capital management that protects the upside while fueling the commercial launch of LYMPHIR™.

Why You Can't Look Away Now (1)(2)(3)(4)(5)(6)(7)(10)(11)

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is hitting that perfect intersection of catalyst, valuation, and momentum.
 

1. The Math is Broken: The value of their CTOR stake alone dwarves their total market cap.
2. The Revenue is Real: $3.9 million in the first quarter, and growing.
3. The News is Fresh: Recent  expansion into gynecologic cancers with Keytruda changes the ceiling.
4. The Big One is Coming: Mino-Lok® is a multi-Billion dollar solution waiting for its final stamp of approval.
    

The radar is pinging. The stellar days are returning. The question isn't whether Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is moving—it's whether you'll be on the right side of the move when the rest of the world wakes up.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:

1. https://finance.yahoo.com/news/citius-pharmaceuticals-inc-reports-fiscal-213000906.html
2. https://finance.yahoo.com/quote/CTXR/
3. https://finance.yahoo.com/quote/CTXR/analysis/
4. https://citiuspharma.com/home/default.aspx
5. https://bit.ly/4qRJbrg
6. https://finance.yahoo.com/news/citius-pharmaceuticals-inc-secures-3-130000986.html
7. https://finance.yahoo.com/news/citius-oncology-inc-announces-first-130000702.html
8. https://finance.yahoo.com/news/citius-oncology-uniphar-sign-european-115529965.html
9. https://finance.yahoo.com/news/citius-pharmaceuticals-inc-secures-3-130000986.html
10. https://finance.yahoo.com/news/citius-pharma-ctxr-becomes-revenue-200027051.html
11. https://finance.yahoo.com/news/citius-oncology-announces-positive-topline-124700182.html
 

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 03/10/2025 and ending on 03/11/2025 (the “Campaign”) to publicly disseminate information about Citius Pharmaceuticals Inc. (CTXR:US). Momentum Media LLC has been compensated $5,000 and are owed an additional $0 for the Campaign. To date we have been paid $70,000. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.